Case Report
The combination of prolonged local drug retention, poor drug redistribution, and inadequate systemic drug concentration may all theoretically contribute to the sparing phenomenon to produce an intralesional injection-like effect. Intralesional injection sites serve as a reservoir to maintain a longer duration of local action. Although this depot effect is more pronounced with lipophilic medications, water-soluble medications, such as methotrexate and even etanercept, have also been used locally. [6, 7] It seemed that the injection site sparing phenomenon was not confined to any particular class of targeting points of monoclonal antibodies, because we observed this effect in both antitumor necrosis factor-alpha and anti-IL-17A drugs [ Table 1 ]. However, injection frequency may play a role because we have not yet observed the same phenomenon after ustekinumab injections, given every 12 weeks, even though ustekinumab is the most commonly prescribed biologics for psoriasis. Repeated injections into the same area at reasonable time intervals may be needed to produce this sparing phenomenon.
A patient (Case 1) showed injection site sparing only with secukinumab injections, but not with previous efalizumab or etanercept. Although his response to secukinumab was only suboptimal, this response was better than with other previous systemic treatments. Thus, inadequate systemic drug concentration may also play a role. Although prior studies have shown the need of a higher drug dose in heavier patients, we suspect that a higher dose of biologics may also benefit patients with extensive or EP, considering the number of inflammatory cells and cytokines in such patients.
Sparing effects occurred in two patients (Cases 5 and 6) when PASI scores decreased slightly after the initiation lesions and because most patients responded so well that all lesions resolved at the same time. In fact, all patients in this case series started with extensive body surface involvement, making injecting into nonlesional skin impossible, and all patients showed an inadequate response to the biologics treatment. The spared lesions then became the only sites suitable for subsequent injections.
Intralesional therapy, including biologics, has been used in psoriasis treatment. [5] Despite a lack of direct evidence, it is conceivable that drug concentration is highest near the injection sites of biologic agents, at least for a short period of time and that the local effects may be longer lasting than expected. of adalimumab treatment [ Table 1 ]. Following further improvements of PASI under regular adalimumab treatment, the sparing effects disappeared. In contrast, injection site sparing occurred at the secondary failure of adalimumab treatment in Case 2. These three patients had previously been treated with etanercept with poor responses and no sparing phenomenon.
ConClusion
We observed an injection site sparing effect in (sub) erythrodermic and extensive psoriasis after biologics therapy. The exact mechanisms underlying this phenomenon remain to be elucidated.
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